WAVEMAN · COMPANY

DXCM · Dexcom Inc

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

DXCM

Name: DEXCOM INC (DXCM) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

DEXCOM INC

MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001093557

FORM 144 · 9☆ WATCH

INSIDER NET · 180D

-$10.8M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

521

13F, latest reported quarter

REVENUE GROWTH

+15.6%

XBRL, annual

NET MARGIN

17.9%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$10.8M over 180 days

-$7.7M over 90 days

below 85% of Medical Devices

CONGRESS

no member of Congress has reported trading it

FUNDS

521 funds added or opened last quarter

more than 92% of Medical Devices

REVENUE

+15.6% year over year

more than 67% of Medical Devices

MARGIN

17.9% net margin

more than 91% of Medical Devices

BUYBACKS

$603.6M repurchased, FY to 2026-06-30

more than 88% of Medical Devices

SHORT

4.7% of shares outstanding short · 3.5 days to cover · settled 2026-07-31

more than 59% of Medical Devices

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$10.8M across 6 people in 180 days.

521 funds added or opened positions in the latest 13F quarter, of 978 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +20.7%

+20.7%12M

INSIDER BUYINSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $10.8M sold by insiders over 180 days, 521 funds added last quarter, $7.3M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG EW TMDX OM

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, DEXCOM INC insiders sold a net $10.8M of stock across 388 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Stern Sadie

EVP Chief People & Culture Off

SELL

2026-08-27

2,565.0

$226.7K

SAYER KEVIN R

Executive Chair

SELL

2026-08-20

19,308.0

$1.7M

SAYER KEVIN R

Executive Chair

SELL

2026-08-20

7,351.0

$667.3K

SAYER KEVIN R

Executive Chair

SELL

2026-08-20

97.0

$8.9K

Brown Michael Jon

EVP Chief Legal Compliance Off

SELL

2026-08-14

1,700.0

$156.3K

388 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 383 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

38,244,137.0 sh

$2.6B

VANGUARD CAPITAL MANAGEMENT LLC

25,209,752.0 sh

$1.7B

VANGUARD PORTFOLIO MANAGEMENT LLC

19,656,540.0 sh

$1.3B

STATE STREET CORP

18,380,806.0 sh

$1.2B

Invesco Ltd.

15,288,133.0 sh

$1.0B

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

SADIE STERN

FILED 2026-08-27

$226.7K

KEVIN R SAYER

FILED 2026-08-20

$2.4M

MICHAEL BROWN

FILED 2026-08-14

$156.3K

Heller Bridgette P

FILED 2026-08-12

$89.3K

FOLETTA MARK G

FILED 2026-08-03

$170.6K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Global X HealthTech ETF

$2.2M POSITION · AS OF 2026-02-28

6.1%

Motley Fool Mid-Cap Growth ETF

$6.5M POSITION · AS OF 2026-02-28

4.9%

Global X Internet of Things ETF

$9.7M POSITION · AS OF 2026-02-28

4.6%

MIG Core ETF

$22.2M POSITION · AS OF 2026-02-28

4.2%

BlackRock Mid-Cap Growth Equity Portfolio

$212.4M POSITION · AS OF 2026-02-27

3.6%

iShares U.S. Medical Devices ETF

$104.0M POSITION · AS OF 2026-03-31

3.3%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 7 registered trials, 5 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

1 ACTIVE

Phase 4

1 ACTIVE

Not applicable

3 ACTIVE

What changed recently

Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom

2026-09-03 · Recruiting → Active Not Recruiting

—

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Executive pay vs shareholder return · Kevin Sayer

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2020

$13.8M

$45.1M

$5.7M

+69%

+33%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$4.7B	$4.0B	$3.6B	$2.9B
GROSS PROFIT	$2.8B	$2.4B	$2.3B	$1.9B
OPERATING INCOME	$911.8M	$600.0M	$597.7M	$391.2M
NET INCOME	$836.3M	$576.2M	$541.5M	$341.2M
EPS (DILUTED)	2.09	1.42	1.30	0.82
OPERATING CASH FLOW	$1.4B	$989.5M	$748.5M	$669.5M
CASH	$917.7M	$606.1M	$566.3M	$642.3M
BUYBACKS	$500.0M	$750.0M	$688.7M	$557.7M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE